Floatz logo

OXALIPLATIN

Colon Adenocarcinoma

Sun Yat-sen UniversitySmall moleculePhase 3Active
BBB
77/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
89/ 100

Competitive context

42 Active assets in the Colon Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 3BBB
Irinotecan
Sun Yat-sen University
Phase 3BBB
Cetuximab
Merck Sharp & Dohme LLC
Phase 3BB
Nivolumab
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3BB
Capecitabine
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 3BB

View all 50 →

Same molecule, other indications

OXALIPLATIN is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
rectal cancerDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →